Evan Lippman, Executive Vice President, Business Development, on August 17, 2026, sold 18,600 shares in Teva Pharmaceutical Industries (TEVA) for $680,291. Following the Form 4 filing with the SEC, Lippman has control over a total of 25,591 ordinary shares of the company, with 25,591 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/818686/000119312526356853/xslF345X05/ownership.xml
Asmau Ahmed, Director, on August 14, 2026, sold 25,000 shares in Quinstreet (QNST) for $515,750. Following the Form 4 filing with the SEC, Ahmed has control over a total of 24,979 common shares of the company, with 24,979 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1117297/000185893626000004/xslF345X05/edgardoc.xml
Alexandros Aldous, General Counsel, on August 14, 2026, sold 35,000 shares in Chefs' Warehouse (CHEF) for $3,883,889. Following the Form 4 filing with the SEC, Aldous has control over a total of 34,442 common shares of the company, with 34,442 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1517175/000094787126000817/xslF345X05/ownership.xml
William Heard, Director, on August 14, 2026, sold 46,400 shares in Anterix (ATEX) for $4,181,095. Following the Form 4 filing with the SEC, Heard has control over a total of 1,679,703 common shares of the company, with 9,365 shares held directly and 1,670,338 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1304492/000203587526000006/xslF345X05/wk-form4_1787089080.xml